Navigation Links
Strategies That Might Lower Blood Pressure Questioned,,

According to a new study simple strategies to improve lifestyle habits may not lower blood pressure in patients with a single high blood pressure reading .//

Researchers investigated whether simple interventions, such as providing patients with an information booklet, encouraging lower sodium intake, and advice for a healthier diet, had more or less of an effect as standard care. Nearly 300 patients without an established history of high blood pressure were randomized into one of eight groups defined by three factors: an information booklet; low sodium, high potassium salt; prompt sheets for high fruit, vegetable, fiber and low fat. Some patients were given a booklet while others were not. Some patients were advised to use a low sodium, high potassium salt while others did not receive advice on this. Finally, some patients received prompt sheets for high fruit, vegetable, fiber and low fat, while others did not receive any of these prompt sheets.

According to the study, none of the interventions altered blood pressure. Brief advice and careful follow-up resulted in 10 percent to 20 percent changes in diet, and the patients were still eating healthier after six months. Although the changes weren’t significant enough to immediately lower the blood pressure, researchers say that these patients will have a lower risk of stroke in the future.
'"/>




Page: 1

Related medicine news :

1. New Strategies For Effective Treatment Of Malaria
2. Experts State Strategies To Increase Good Cholesterol
3. Strategies to prevent the rising tide of the epidemic of chronic diseases
4. Strategies To Boost Living Donor Kidney Transplants
5. Japan planning Strategies to combat Bird flu
6. Need of the Hour: Viable Strategies against AIDS
7. Kellogg Warned Against Its Marketing Strategies
8. India to Spend Rs.10 bn on Polio Eradication Strategies
9. Strategies To Fight AIDS
10. Global AIDS Conference Calls for Long-term Strategies
11. Strategies by the State Government to eradicate Chikungunya
Post Your Comments:
(Date:10/7/2008)...alth-related Questions for Tonight,s,Presidential ...- WebMD, the leading source of,health information,...ial,candidates, proposed health care policies, loc...t the candidates, stance on health insurance, medi... public health issues., The in-depth coverage is ...
(Date:10/7/2008)...PRNewswire-USNewswire/ -- The Ohio Nurses,Associat...ced today its,final round of endorsed candidates f...o Senate:, SD 26 Karen Gillmor (R) Tiffin, Ohio ...(R) Grove City;, HD 28 Connie Pillich (D) Cincinn...These ONA-endorsed candidates for the Ohio General...
(Date:10/7/2008)...wswire-USNewswire/ -- Kristi Yamaguchi, Olympic,Go... the Stars, has been,named chairperson for the 200...gn in an effort to help raise funds in support of ...e and promote lung health., The American Lung Ass...o conquer Tuberculosis. Today, the Lung Associatio...
(Date:10/7/2008)...ar to more expensive whole-leg color ultrasound, ...lthDay News) -- An older, simpler test to look for...osis, or DVT -- is as effective as a newer, more e...searchers found that 2-point ultrasonography of th...trasound -- was as good at detecting DVT as the ne...
Breaking Medicine News(10 mins):Health News:WebMD Highlights Presidential Candidates' Views on Health Care 2Health News:ONA-PCE Announces Final Round of Endorsed Candidates for Ohio General Assembly 2Health News:ONA-PCE Announces Final Round of Endorsed Candidates for Ohio General Assembly 3Health News:Kristi Yamaguchi Chairs American Lung Association Christmas Seals Campaign 2Health News:Simpler Test May Be Best for Diagnosing Blood Clots in Leg 2Health News:Simpler Test May Be Best for Diagnosing Blood Clots in Leg 3
...rom a serious kidney ailment died Saturday after j...here//, apparently because he could not afford the...dow of the nephrology ward of the Sanjay Gandhi Po...ces, where he was being treated, hospital sources ...
...ug has been for the first time given the green sig... emotional disturbances// in children and teenager...ug Administration. An antipsychotic drug generally...Risperidone will thus become the first one in its ...
...on form of adult leukemia will require blocking mu... researchers at The University of Texas M. D. Ande... the journal Blood. The research team examined blo...ts with acute myelogenous leukemia (AML) and then ...
...or logical applications apparently also works very...ogy Professor Randall O'Reilly of the University//...much light in the recesses of research trying to f...elligently. While reviewing computer models of th...
Other Medicine News:Health News:Three Molecular Triggers Threaten Leukemia Patients 2Health News:Three Molecular Triggers Threaten Leukemia Patients 3
(Date:10/7/2008)...ented Immunologic Changes Induced by ...nal Data Indicates Potential in Treating Inflammat...ire/ -- Alba Therapeutics Corporation,presented re...merican,College of Gastroenterology (ACG) 2008 Ann...004, the first Phase IIa trial conducted in celiac...
(Date:10/7/2008)... Annual Scientific Meeting -, ORLANDO, Fla., Oct....als, Inc. (formerly Microbia, Inc.) and Forest Lab...presentation of results from a Phase,2b study asse...ients with,irritable bowel syndrome with constipat...nce- daily oral dosing of linaclotide, across a ra...
(Date:10/7/2008)...acebo-Controlled Phase II Study Shows Sta... MOUNTAIN VIEW, California, October 7 /PRNewswire...ature Phase II data from the,therapeutic prostate ...n,obtained as part of the recently entered partner...he US., The results from the Phase II prospective...
(Date:10/7/2008)...Newswire-FirstCall/ --, - 125 Patient, Prospectiv...ws Statistically Significant Improved Overall Surv...e phase II data from the,therapeutic prostate canc...tained as part of the recently entered partnership...S., The results from the Phase II prospective ran...
Breaking Medicine Technology:Alba Therapeutics Presents New Data for Larazotide Acetate at the 2008 American College of Gastroenterology Annual Scientific Meeting 2Alba Therapeutics Presents New Data for Larazotide Acetate at the 2008 American College of Gastroenterology Annual Scientific Meeting 3Alba Therapeutics Presents New Data for Larazotide Acetate at the 2008 American College of Gastroenterology Annual Scientific Meeting 4Alba Therapeutics Presents New Data for Larazotide Acetate at the 2008 American College of Gastroenterology Annual Scientific Meeting 5Alba Therapeutics Presents New Data for Larazotide Acetate at the 2008 American College of Gastroenterology Annual Scientific Meeting 6Ironwood and Forest Present Positive Phase 2b Study Results for Linaclotide in Patients With Irritable Bowel Syndrome With Constipation 2Ironwood and Forest Present Positive Phase 2b Study Results for Linaclotide in Patients With Irritable Bowel Syndrome With Constipation 3Ironwood and Forest Present Positive Phase 2b Study Results for Linaclotide in Patients With Irritable Bowel Syndrome With Constipation 4Ironwood and Forest Present Positive Phase 2b Study Results for Linaclotide in Patients With Irritable Bowel Syndrome With Constipation 5BN ImmunoTherapeutics Announces Positive Mature Phase II Results From Newly Acquired Prostate Cancer Vaccine 2BN ImmunoTherapeutics Announces Positive Mature Phase II Results From Newly Acquired Prostate Cancer Vaccine 3BN ImmunoTherapeutics Announces Positive Mature Phase II Results From Newly Acquired Prostate Cancer Vaccine 4Bavarian Nordic Announces Positive Mature Phase II Results From Newly Acquired Prostate Cancer Vaccine 2Bavarian Nordic Announces Positive Mature Phase II Results From Newly Acquired Prostate Cancer Vaccine 3Bavarian Nordic Announces Positive Mature Phase II Results From Newly Acquired Prostate Cancer Vaccine 4Bavarian Nordic Announces Positive Mature Phase II Results From Newly Acquired Prostate Cancer Vaccine 5Favrille Provides Update on Timing of Analysis from Pivotal Phase 3 Clinical Trial 3B Reports Third Quarter 2007 Financial Results 664 1Favrille Provides Update on Timing of Analysis from Pivotal Phase 3 Clinical Trial 3B Reports Third Quarter 2007 Financial Results 664 2Favrille Provides Update on Timing of Analysis from Pivotal Phase 3 Clinical Trial 3B Reports Third Quarter 2007 Financial Results 664 3Favrille Provides Update on Timing of Analysis from Pivotal Phase 3 Clinical Trial 3B Reports Third Quarter 2007 Financial Results 664 4Favrille Provides Update on Timing of Analysis from Pivotal Phase 3 Clinical Trial 3B Reports Third Quarter 2007 Financial Results 664 5Favrille Provides Update on Timing of Analysis from Pivotal Phase 3 Clinical Trial 3B Reports Third Quarter 2007 Financial Results 664 6Favrille Provides Update on Timing of Analysis from Pivotal Phase 3 Clinical Trial 3B Reports Third Quarter 2007 Financial Results 664 7Favrille Provides Update on Timing of Analysis from Pivotal Phase 3 Clinical Trial 3B Reports Third Quarter 2007 Financial Results 664 8Favrille Provides Update on Timing of Analysis from Pivotal Phase 3 Clinical Trial 3B Reports Third Quarter 2007 Financial Results 664 9Meningitis Shot Available Effective Year Round 4629 1Meningitis Shot Available Effective Year Round 4629 2Meningitis Shot Available Effective Year Round 4629 3Staying sharp in San Diego 4626 1Gentiva 28R 29 Health Services to Present November 7 at CIBC Healthcare Conference in New York 4623 1Gentiva 28R 29 Health Services to Present November 7 at CIBC Healthcare Conference in New York 4623 2Gentiva 28R 29 Health Services to Present November 7 at CIBC Healthcare Conference in New York 4623 3
...7 /PRNewswire-FirstCall/ --,Pharmacyclics, Inc. an... novel histone deacetylase (HDAC) inhibitor and,Br...esentations,will take place at the American Associ...ng being held April 14-18, 2007, at the Los,Angele...e presentations are as follows:, Sunday, Apri...
...t EASL Conference in Barcelona,Spain, VANCOUVER a...Call/ - MIGENIX Inc. , a clinical-stage developer,... top-line results,confirming the previously announ... evidence of clinical benefit, safety and,tolerabi...osidase,inhibitor, celgosivir (MX-3253), in combin...
Other Medicine Technology:Pharmacyclics Announces Presentations on Its Novel and Selective,HDAC and Bruton's Tyrosine Kinase Inhibitor Compounds 2Pharmacyclics Announces Presentations on Its Novel and Selective,HDAC and Bruton's Tyrosine Kinase Inhibitor Compounds 3Pharmacyclics Announces Presentations on Its Novel and Selective,HDAC and Bruton's Tyrosine Kinase Inhibitor Compounds 4New Clinical Study Results Indicate Higher Early Virologic Response,with Celgosivir Combination Therapy in HCV Non-Responders 2New Clinical Study Results Indicate Higher Early Virologic Response,with Celgosivir Combination Therapy in HCV Non-Responders 3New Clinical Study Results Indicate Higher Early Virologic Response,with Celgosivir Combination Therapy in HCV Non-Responders 4New Clinical Study Results Indicate Higher Early Virologic Response,with Celgosivir Combination Therapy in HCV Non-Responders 5New Clinical Study Results Indicate Higher Early Virologic Response,with Celgosivir Combination Therapy in HCV Non-Responders 6New Clinical Study Results Indicate Higher Early Virologic Response,with Celgosivir Combination Therapy in HCV Non-Responders 7New Clinical Study Results Indicate Higher Early Virologic Response,with Celgosivir Combination Therapy in HCV Non-Responders 8
Angled 60 degree blades 5.5 mm.
Accurately tests for Nystagmus when rotated at 8-10 rpm. Drums are 10" high by 8" diameter. Light weight drum of professional quality with ball bearings for effortless spin mechanism. For use 24 to 3
Eschenbach's new 2636 series of stand magnifiers delivers the benefits of high power and a large fields of view. Using a unique doublet lens design, the 2636 offers the highest power recatngular lens
This Illuminated Stand Magnifier offers versatility across a number of different applications. Both the lens and the light are adjustable. Simply tilt the lens and small hand held objects can be work
Medicine Products: